Capitalizing on AKT signaling to inhibit hepatocellular carcinoma cell proliferation.
Singh
Rajat
R
Department of Medicine and Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.
Czaja
Mark J
MJ
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D064413:3-Phosphoinositide-Dependent Protein Kinases; D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D049109:Cell Proliferation / Q000187:drug effects; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
D015056:1-Methyl-3-isobutylxanthine; D064413:3-Phosphoinositide-Dependent Protein Kinases; D015124:8-Bromo Cyclic Adenosine Monophosphate; D005576:Colforsin; D000242:Cyclic AMP; D019869:Phosphatidylinositol 3-Kinases; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt